News

Bills emerge to increase birth control access


 

References

There’s been a flurry of legislative activity on Capitol Hill and at state houses around the country aimed at improving access to contraception. But there are still deep divides on the best way to achieve that access.

At the federal level, there are two competing bills that address access to contraceptives.

The first – the Allowing Greater Access to Safe and Effective Contraceptive Act (S. 1438) – introduced in May by Sen. Cory Gardner (R-Colo.) and Sen. Kelly Ayotte (R-N.H.), would incentivize manufacturers of “routine-use contraceptives” to file an application with the Food and Drug Administration to switch their products from prescription to over the counter (OTC). The bill would allow for priority review for these products and waive the usual FDA filing fee.

The legislation would also repeal the Affordable Care Act’s restriction on the use of health, medical, and flexible savings accounts to purchase OTC drugs without a prescription.

Despite the fact that the bill is aimed at encouraging the switch of contraceptives to OTC products, it’s been criticized by some reproductive health advocates for not adequately addressing the potential for increased costs if women purchase OTC contraceptives not covered by insurance.

oral contraceptive Fuse/ThinkStockPhotos.com

Senate Democrats responded with their own birth control legislation. The Affordability Is Access Act (S. 1532), introduced in June by Sen. Patty Murray (D-Wash.), aims to build on the no-cost coverage for contraception in the Affordable Care Act by ensuring that if the FDA approves oral contraceptives for OTC use, they will be covered without cost sharing even though they are not prescription products.

Affordability at issue

The American Congress of Obstetricians and Gynecologists is backing Sen. Murray’s bill.

In an interview, Dr. Mark S. DeFrancesco, ACOG president, said he is pleased to see proposals from both sides of the aisle emerge on this topic because ACOG has long supported the concept of OTC sale of oral contraceptives. But the GOP-backed proposal does not address the issue of copays and insurance coverage, said Dr. DeFrancesco, who is a managing partner at Westwood Women’s Health in Waterbury, Conn.

Dr. Mark S. DeFrancesco

Dr. Mark S. DeFrancesco

“An unintended consequence could be, ironically, that it may decrease access for women because if contraceptives are reclassified as nonformulary drugs by going over the counter, can insurance companies say they’re not going to cover them as they don’t cover aspirin, for instance?” Dr. DeFrancesco said. “That’s our concern: that well-intended legislation could have a backfire effect.”

Missed opportunity for screening?

Not everyone favors moving contraceptives over the counter. Dr. W. David Hager, who practices at Baptist Health Medical Group Women’s Care in Lexington, Ky., expressed concern that providing OTC access to contraceptives would hinder the physician-patient relationship and impact screening efforts.

“One of the big advantages for me as a practicing ob.gyn. is to have face-to-face conversations, to be able to discuss risks and benefits, and to counsel young patients about the choices that they are making, to make sure they are making educated, informed choices,” Dr. Hager said.

A shift to OTC access for contraceptives could potentially decrease the uptake of human papillomavirus (HPV) vaccination, said Dr. Hager, who in the early 2000s served on the FDA’s Advisory Committee for Reproductive Health Drugs.

Dr. David Hager

Dr. David Hager

“We’re already at less than 50% implementation with Gardasil, and this may further decrease that,” he said. “It may delay Pap test screening and HPV screening if women choose after age 21 to just purchase over-the-counter contraceptives. It may delay well-woman screening, where women come in just for a wellness exam. And, in my opinion, it eliminates the potential for discussion of any contraindications to birth control pills. Granted, those are not many, but there are some patients who are not ideal candidates for oral contraceptives. I think it potentially takes a cohort of the highest-risk women and removes them from that potential screening and counseling session.”

Dr. DeFrancesco said he knows from experience that patients will come to see their ob.gyn. regularly just because it’s the right thing to do.

“There could be a small percentage of people who say ‘now I really don’t have to see the doctor, because that’s the only reason I was going,’ ” he said. “The good news about more people being covered with insurance is that at least people are more empowered to go to the physician’s office or the provider’s office to get care.”

States take the lead

While the federal bills are drawing attention, they are no closer to becoming law. But it’s a different story at the state level.

Pages

Recommended Reading

LARCs appear safe in adolescents with CVD
MDedge Endocrinology
LARC use leads to dramatic drop in teen pregnancies
MDedge Endocrinology
ACA contraception mandate hits legal snag
MDedge Endocrinology
Legal battle over contraception mandate rages on
MDedge Endocrinology
Supreme Court gives Catholic organizations a pass on contraception mandate
MDedge Endocrinology
New stroke guidelines focus on women’s risks
MDedge Endocrinology
Hormonal birth control linked to gestational diabetes
MDedge Endocrinology
Estrogen-containing OCs cloud measurement of ovarian reserve
MDedge Endocrinology
Lower DMPA dose provides comparable efficacy, tolerability in adolescents
MDedge Endocrinology
NASPAG: Obesity raises unique contraceptive concerns in teens
MDedge Endocrinology